Drugs / Methoxyethyl Etomidate Hydrochloride
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06822153 | Nov 2023 | cardiac rhythm disease | Ahon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06822114 | Jul 2023 | — | Ahon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methoxyethyl Etomidate Hydrochloride | “Clinical Trial of the Effect of Methoxyethyl Etomidate Hydrochloride on the QT Interval of the Heart” NCT06822153 ↗ |
| Route | Intravenous | “a single intravenous injection was given slowly” NCT06822114 ↗ |